These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 21826093)

  • 1. Pharmacogenetics: implications for therapy in rheumatic diseases.
    Davila L; Ranganathan P
    Nat Rev Rheumatol; 2011 Aug; 7(9):537-50. PubMed ID: 21826093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of therapies in rheumatoid arthritis.
    Ranganathan P
    Drugs Today (Barc); 2005 Dec; 41(12):799-814. PubMed ID: 16474855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis.
    Aluko A; Ranganathan P
    Methods Mol Biol; 2022; 2547():527-567. PubMed ID: 36068476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate pharmacogenetics in rheumatoid arthritis.
    Brinker RR; Ranganathan P
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S33-9. PubMed ID: 21044431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics in pediatric rheumatology.
    Becker ML
    Curr Opin Rheumatol; 2012 Sep; 24(5):541-7. PubMed ID: 22732686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine.
    Umićević Mirkov M; Coenen MJ
    Pharmacogenomics; 2013 Mar; 14(4):425-44. PubMed ID: 23438889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics in rheumatoid arthritis.
    Sen D; Paul JR; Ranganathan P
    Methods Mol Biol; 2014; 1175():625-60. PubMed ID: 25150878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics in the rheumatic diseases.
    Cronstein BN
    Bull NYU Hosp Jt Dis; 2006; 64(1-2):16-9. PubMed ID: 17121484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology.
    Ferraccioli G; De Santis M; Tolusso B
    Pharmacogenomics; 2004 Dec; 5(8):1107-16. PubMed ID: 15584877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field.
    Siva C; Yokoyama WM; McLeod HL
    Rheumatology (Oxford); 2002 Nov; 41(11):1273-9. PubMed ID: 12422000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic of antirheumatic treatments: clinical implications.
    Ferraccioli G; Tolusso B; De Santis M
    Pharmacogenomics J; 2007 Feb; 7(1):2-9. PubMed ID: 16702980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response.
    Asanuma Y; Xie HG; Stein CM
    Arthritis Rheum; 2005 May; 52(5):1349-59. PubMed ID: 15880820
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacogenetics and pharmacogenomics in rheumatology.
    Szekanecz Z; Meskó B; Poliska S; Váncsa A; Szamosi S; Végh E; Simkovics E; Laki J; Kurkó J; Besenyei T; Mikecz K; Glant TT; Nagy L
    Immunol Res; 2013 Jul; 56(2-3):325-33. PubMed ID: 23564183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The possible clinical application of pharmacogenetics in rheumatology.
    Ferraccioli G
    J Rheumatol; 2003 Dec; 30(12):2517-20. PubMed ID: 14719186
    [No Abstract]   [Full Text] [Related]  

  • 15. Precision Medicine: Towards Individualized Dosing in Pediatric Rheumatology.
    Balevic SJ; Sagcal-Gironella ACP
    Rheum Dis Clin North Am; 2022 Feb; 48(1):305-330. PubMed ID: 34798954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of disease-modifying anti-rheumatic drugs.
    Tanaka E; Taniguchi A; Urano W; Yamanaka H; Kamatani N
    Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):233-47. PubMed ID: 15121042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
    Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Personalized medicine in cytokine-targeted therapy].
    Behrens F; Köhm M
    Z Rheumatol; 2013 Feb; 72(1):41-8. PubMed ID: 23392600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.